Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Vista Investment Management

Vista Investment Management increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,001 shares of the medical research company’s stock after buying an additional 228 shares during the period. Thermo Fisher Scientific comprises approximately 1.2% of Vista Investment Management’s holdings, making the stock its 21st biggest position. Vista Investment Management’s holdings in Thermo Fisher Scientific were worth $2,654,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of TMO. Northwest Financial Advisors bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $29,000. Cape Investment Advisory Inc. raised its position in shares of Thermo Fisher Scientific by 52.0% during the 4th quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock worth $40,000 after buying an additional 26 shares in the last quarter. Raleigh Capital Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after purchasing an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after purchasing an additional 46 shares in the last quarter. Finally, Frazier Financial Advisors LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $49,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,000 shares of company stock worth $12,532,780. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.0 %

Shares of NYSE:TMO traded down $5.59 during mid-day trading on Tuesday, reaching $575.89. The stock had a trading volume of 239,465 shares, compared to its average volume of 1,481,074. The firm has a market cap of $219.83 billion, a PE ratio of 37.30, a price-to-earnings-growth ratio of 2.71 and a beta of 0.79. The firm has a 50 day simple moving average of $575.21 and a two-hundred day simple moving average of $556.45. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on TMO shares. The Goldman Sachs Group boosted their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Citigroup started coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 target price for the company. Deutsche Bank Aktiengesellschaft upped their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Finally, Barclays upped their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday, April 25th. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $607.94.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.